Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Inotuzumab ozogamicin
Brand Name Besponsa®
Payment Category Medicare Part B
Year Introduced 2017
Type of Drug CD-22 directed antibody-drug conjugate
Manufacturer Pfizer
Medical Affairs Questions (date verified) 800.438.1985
Coverage & Reimbursement Questions 866.706.2400
HCPCS J9229
Billing Unit 0.1 mg
Medicare Payment Limit (Effective January 1, 2021) $2,341.30

FDA-Approved Indication(s)

  • Indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. (8/17/17)

Approved Indication(s) with Orphan Drug Status Treatment of B-cell acute lymphoblastic leukemia
ICD-10 Code(s) for Labeled Indication(s) Acute lymphoblastic leukemia, not having achieved remission [C91.00] or in relapse [C91.02]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US